Skip to main content
Signal8
Launch Terminal

Wave Life Sciences, Inc. (WVE)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

NASDAQ:WVEHealthcare
-1.10%$3.59
AH$3.63+1.11%vs close
Mkt Cap$708.05M
Float124.48M
O/S197.23M
Vol
$ Vol
RVOL
Inst Own93.1%
SI17.0%
Earnings
Dilution
Wave Life Sciences Ltd. logoNASDAQ:WVE$3.59-1.10%
Upcoming Catalysts
  • WVE-007READOUT
    Cash runway at this date: 18mo
    Fourth quarter of 2026~8w8-K
  • WVE-006READOUT
    Cash runway at this date: 18mo
    Fourth quarter of 2026~8w8-K
Phase Distribution
14 lead-sponsored trials·4 active·3 completed
Phase 12
Phase 1/210
Phase 21
Phase 2/31
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • GSKMILESTONE
    $12M upfront/ $375M totalDec 31, 2026
    GalNAc-siRNA hepatology candidate (SpiNA design)
  • GSKMILESTONE
    $12M upfront/ $375M totalSep 30, 2026
    GalNAc-siRNA (SpiNA) hepatology development candidate
Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Terminated

    Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

    WVE-210201 (suvodirsen), Placebo

    Duchenne Muscular Dystrophy

    Enrollment
    6
    Start
    Sep 2019
    Primary Completion
    Dec 2019
    Completion
    Jan 2020
    NCT03907072
  • Phase 2
    Enrolling by invitation

    Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

    WVE-N531

    Duchenne Muscular Dystrophy

    Enrollment
    175
    Start
    Dec 2025
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT07209332
  • Phase 1/2
    Terminated

    Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

    WVE-120101, Placebo

    Huntington's Disease

    Enrollment
    61
    Start
    Jul 2017
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT03225833
  • Phase 1/2
    Terminated

    Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

    WVE-120102, Placebo

    Huntington's Disease

    Enrollment
    88
    Start
    Jul 2017
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT03225846
  • Phase 1/2
    Terminated

    Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

    WVE-120101

    Huntington Disease

    Enrollment
    27
    Start
    Apr 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04617847
  • Phase 1/2
    Terminated

    Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

    WVE-120102

    Huntington Disease

    Enrollment
    36
    Start
    Sep 2019
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04617860
  • Phase 1/2
    Active, not recruiting

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

    WVE-N531

    Duchenne Muscular Dystrophy

    Enrollment
    25
    Start
    Sep 2021
    Primary Completion
    Oct 2026est.
    Completion
    Apr 2027est.
    NCT04906460
  • Phase 1/2
    Terminated

    Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

    WVE-004, Placebo

    ALS, FTD

    Enrollment
    35
    Start
    Jun 2021
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT04931862
  • Phase 1/2
    Completed

    Study of WVE-003 in Patients With Huntington's Disease

    SAD: 30mg WVE-003, SAD: 60mg WVE-003

    Huntington Disease

    Enrollment
    47
    Start
    Sep 2021
    Primary Completion
    May 2024
    Completion
    May 2024
    NCT05032196
  • Phase 1/2
    Terminated

    Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

    WVE-004 10 mg Q12W

    Amyotrophic Lateral Sclerosis, Frontotemporal Dementia

    Enrollment
    8
    Start
    Dec 2022
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT05683860
  • Phase 1/2
    Recruiting

    A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

    WVE-006

    Alpha-1 Antitrypsin Deficiency

    Enrollment
    48
    Start
    Jul 2024
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT06405633
  • Phase 1/2
    Recruiting

    A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

    WVE-007

    Overweight and Obesity

    Enrollment
    400
    Start
    Jan 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT06842186
  • Phase 1
    Completed

    Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

    WVE-210201, Placebo

    Duchenne Muscular Dystrophy

    Enrollment
    36
    Start
    Jan 2018
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT03508947
  • Phase 1
    Completed

    A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

    WVE-006

    Alpha-1 Antitrypsin Deficiency (AATD)

    Enrollment
    47
    Start
    Nov 2023
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT06186492
Search ClinicalTrials.gov for “Wave Life Sciences”